CARTER ROBERT B 4

What Happened

• Robert B. Carter, a director of Quest Diagnostics (DGX), acquired 7 shares on 2026-04-20 at $194.70 per share, a total value of about $1,363. The shares were obtained through a dividend reinvestment mechanism, so this is a purchase (routine reinvestment) rather than an open-market bullish bet.

Key Details

• Transaction date and price: 2026-04-20 — 7 shares at $194.70 each.
• Total value: approximately $1,363.
• Method: Acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker (see footnote).
• Filing date / timeliness: Form filed 2026-04-24 and marked with an "L" (late). Footnote F1 states the shares were eligible for deferred reporting on Form 5 under Rule 16a-6 and the reporting person chose to report the transaction early on this Form 4.
• Shares owned after transaction: not specified in this filing.

Context

• This was a small, routine dividend reinvestment purchase by a director. Such DRIP transactions are common and typically reflect automatic reinvestment of dividends rather than new, discretionary purchases signaling a change in view.
• The filing’s timeliness note indicates reporting nuances (deferment eligibility vs. early reporting) rather than a clear trading-policy violation; no indication of option exercises, gifts, tax withholding, or a 10% owner change in this record.